Moleculin Biotech, Inc. (MBRX) Stock Dipped in Premarket Despite any Visible Reason
Moleculin Biotech, Inc. (MBRX) is a late clinical-stage biotherapeutics company primarily engaged in the development of a large platform of drugs for treating highly resistant